Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report
| Autor: | Yoshinori Imamura, Yasuko Hyogo, Naomi Kiyota, Masanori Toyoda, Hirotaka Suto, Hironobu Minami, Satoshi Sai, Kei Takenaka, Naoe Jimbo, Naoko Chayahara, Yohei Funakoshi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Stem cell factor intimal sarcoma Pazopanib 03 medical and health sciences 0302 clinical medicine Growth factor receptor pulmonary artery case reports medicine pazopanib biology Oncogene business.industry Cancer Articles platelet-derived growth factor receptor medicine.disease Molecular medicine Oncology 030220 oncology & carcinogenesis biology.protein Cancer research 030211 gastroenterology & hepatology business Tyrosine kinase Platelet-derived growth factor receptor medicine.drug vascular endothelial growth factor receptor |
| Zdroj: | Molecular and Clinical Oncology |
| ISSN: | 2049-9450 |
| Popis: | Intimal sarcoma of the pulmonary artery (PAIS) is a rare disease with a poor prognosis. Pazopanib, which has been indicated in metastatic non-adipocytic soft-tissue sarcomas and is expected to be active in PAIS, is a multi-kinase inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor. The present study reports findings related to two cases of PAIS with PDGF and VEGF expression following treatment with pazopanib. A case with a moderate to strong expression of PDGFR-α and -β presented a long-term stable disease when treated with pazopanib (progression-free survival, 5.8 months). In a second case with a weak expression of PDGFR-α and -β, the disease progressed rapidly on pazopanib (progression-free survival, 1.1 months). VEGFR-2 was not expressed in the tumors of both cases. The level of PDGFR expression in the tumor tissue may therefore be predictive of pazopanib efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |